Role of 18F-fluorodeoxyglucose positron emission tomography–contrast-enhanced computed tomography in detection of early recurrence with peritoneal disease in a case of adrenocortical carcinoma



   Table of Contents      INTERESTING IMAGE Year : 2022  |  Volume : 37  |  Issue : 4  |  Page : 389-391  

Role of 18F-fluorodeoxyglucose positron emission tomography–contrast-enhanced computed tomography in detection of early recurrence with peritoneal disease in a case of adrenocortical carcinoma

Debdip Roy, Melvika Pereira, Divya Shivdasani, Natasha Singh, Shreya Dang, Rachita Rungta
Department of Nuclear Medicine and Molecular Imaging, P. D. Hinduja National Hospital and MRC, Mumbai, Maharashtra, India

Date of Submission09-Feb-2022Date of Decision23-Mar-2022Date of Acceptance04-Apr-2022Date of Web Publication02-Dec-2022

Correspondence Address:
Dr. Debdip Roy
Department of Nuclear Medicine and Molecular Imaging, P. D. Hinduja National Hospital and MRC, Mumbai, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Crossref citationsCheck

DOI: 10.4103/ijnm.ijnm_33_22

Rights and Permissions

   Abstract 


Adrenocortical carcinoma (ACC) is an uncommon and highly aggressive malignancy with a poor prognosis. Common sites of metastasis are lung, liver, and lymph nodes. We present a case of ACC in a 54-year-old female with an early disease recurrence of unusual hypervascular peritoneal metastatic abdominal-pelvic deposits detected on 18F-fluorodeoxyglucose positron emission tomography–contrast-enhanced computed tomography scan.

Keywords: 18F-fluorodeoxyglucose positron emission tomography–computed tomography, adrenocortical carcinoma, peritoneal metastasis


How to cite this article:
Roy D, Pereira M, Shivdasani D, Singh N, Dang S, Rungta R. Role of 18F-fluorodeoxyglucose positron emission tomography–contrast-enhanced computed tomography in detection of early recurrence with peritoneal disease in a case of adrenocortical carcinoma. Indian J Nucl Med 2022;37:389-91
How to cite this URL:
Roy D, Pereira M, Shivdasani D, Singh N, Dang S, Rungta R. Role of 18F-fluorodeoxyglucose positron emission tomography–contrast-enhanced computed tomography in detection of early recurrence with peritoneal disease in a case of adrenocortical carcinoma. Indian J Nucl Med [serial online] 2022 [cited 2022 Dec 3];37:389-91. Available from: 
https://www.ijnm.in/text.asp?2022/37/4/389/361992

A 54-year-old female presented with complaints of sudden-onset hypertension, hirsutism, and hot flushes. Initial diagnostic ultrasound and computed tomography (CT) workup detected a left adrenal mass lesion suggesting primary neoplasm. Staging 18F-fluorodeoxyglucose positron emission tomography-CT (18F-FDG PET-CT) scan [Figure 1] coronal PET, fused coronal PET-CT [Figure 1]a and [Figure 1]b, and corresponding fused transaxial images [Figure 1]c, [Figure 1]d, [Figure 1]e, [Figure 1]f, [Figure 1]g, [Figure 1]h revealed an FDG-avid (SUVmax: 18.3) large heterogeneously enhancing lobulated left adrenal lesion with areas of necrosis. The lesion is abutting the left kidney and spleen, with tumor thrombus infiltrating the left suprarenal, left renal, left ovarian vein and adjacent inferior vena cava. The patient underwent left adrenalectomy, left nephrectomy, and caval thrombectomy. Histopathology revealed adrenocortical carcinoma (ACC), an uncommon epithelial malignancy of adrenal cortical cells with an unfavorable prognosis. ACC has a female predilection, with the left adrenal being commonly involved.[1],[2] The patient was symptom free until just 5 months post surgery, and she presented with left flank pain. Triple-phase contrast-enhanced CT (CECT) abdomen-pelvis scan revealed multiple new-onset arterially hyperenhancing small nodular peritoneal deposits scattered in the abdomen-pelvis [Figure 2]c, [Figure 2]e, [Figure 2]g, and [Figure 2]i which appeared isodense to abdominal aorta on subsequent phases. The abovementioned lesions demonstrated low-grade FDG avidity with SUVmax 3.8 as seen on FDG PET-CT scan coronal PET, fused PET-CT [Figure 2]a and [Figure 2]b, and corresponding fused transaxial images [Figure 2]d, [Figure 2]f, [Figure 2]h, and [Figure 2]j. These scan findings appeared very unusual for ACC metastasis and demonstrated an appearance of splenosis (although the spleen was intact post surgery). Common sites of ACC metastasis include lung, liver, and lymph nodes, with peritoneal involvement being extremely rare.[3],[4] Studies suggest that FDG PET-CT has a greater positive likelihood ratio than CT to identify liver and abdominal ACC recurrences and thus change in management strategy.[5],[6],[7] ACC being an aggressive neoplasm, metastatic disease is known to demonstrate higher FDG avidity, unlike that seen in our case. The patient underwent exploratory laparotomy with excision of multiple peritoneal nodules, and histopathology revealed metastatic ACC deposits. From this case, we learn that ACC metastatic recurrence can involve rarely only the peritoneum quite early post surgery, appearing as hypervascular nodules and presenting low FDG uptake. 18F-FDG PET-CECT (triple-phase protocol) scan would be most appropriate to confidently detect the lesions.

Figure 1: Staging 18F-fluorodeoxyglucose positron emission tomography–computed tomography scan coronal positron emission tomography (a), fused coronal positron emission tomography–computed tomography (b), and corresponding transaxial images (c-h) showing fluorodeoxyglucose-avid large heterogeneously enhancing left adrenal lesion with tumor thrombus infiltrating the left renal vein and adjacent inferior vena cava

Click here to view

Figure 2: 18F-fluorodeoxyglucose positron emission tomography–computed tomography scan coronal positron emission tomography (a), fused coronal positron emission tomography–computed tomography (b), contrast-enhanced computed tomography abdomen-pelvis (c, e, g, and i) and corresponding fused transaxial positron emission tomography–computed tomography images (d, f, h, and j) showing arterially hyperenhancing small nodular peritoneal deposits with low fluorodeoxyglucose avidity

Click here to view

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given her consent for her images and other clinical information to be reported in the journal. The patient understands that her name and initials will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 

   References Top
1.Ng L, Libertino JM. Adrenocortical carcinoma: Diagnosis, evaluation and treatment. J Urol 2003;169:5-11.  Back to cited text no. 1
    2.Takeuchi S, Balachandran A, Habra MA, Phan AT, Bassett RL Jr., Macapinlac HA, et al. Impact of 18F-FDG PET/CT on the management of adrenocortical carcinoma: Analysis of 106 patients. Eur J Nucl Med Mol Imaging 2014;41:2066-73.  Back to cited text no. 2
    3.Owen DH, Patel S, Wei L, Phay JE, Shirley LA, Kirschner LS, et al. Metastatic adrenocortical carcinoma: A single institutional experience. Horm Cancer 2019;10:161-7.  Back to cited text no. 3
    4.Kumar T, Nigam JS, Sharma S, Kumari M, Pandey J. Uncommon metastasizing site of adrenocortical carcinoma. Cureus 2021;13:e15267.  Back to cited text no. 4
    5.Ardito A, Massaglia C, Pelosi E, Zaggia B, Basile V, Brambilla R, et al. 18F-FDG PET/CT in the post-operative monitoring of patients with adrenocortical carcinoma. Eur J Endocrinol 2015;173:749-56.  Back to cited text no. 5
    6.Leboulleux S, Dromain C, Bonniaud G, Aupérin A, Caillou B, Lumbroso J, et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: A prospective comparison with computed tomography. J Clin Endocrinol Metab 2006;91:920-5.  Back to cited text no. 6
    7.Mackie GC, Shulkin BL, Ribeiro RC, Worden FP, Gauger PG, Mody RJ, et al. Use of [18F] fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2006;91:2665-71.  Back to cited text no. 7
    
  [Figure 1], [Figure 2]
  Top   

Comments (0)

No login
gif